Drug intelligence / Profile preview

dmt + harmine

Development stage
Unknown
Lead developer
Reconnect Labs
Modality
Implantable Devices → Device-based Delivery → Drug Delivery Systems, Small Molecules, Transdermal Patches → Device-based Delivery → Drug Delivery Systems, Inhalation Devices → Device-based Delivery → Drug Delivery Systems
Administration
Oral, Intranasal, Buccal
01

Overview

DMT + harmine is a combination of N,N-dimethyltryptamine (DMT), a potent psychedelic tryptamine, and harmine, a reversible inhibitor of monoamine oxidase A (MAO-A). This combination is inspired by the traditional Amazonian brew ayahuasca. When administered together, harmine inhibits MAO-A in the gut and liver, preventing the rapid breakdown of orally or nasally administered DMT. This allows DMT to become bioavailable and active for an extended period when taken by routes other than smoking or injection. The result is a phenomenologically rich psychedelic experience characterized by vivid visual hallucinations, mystical experiences, psychological insights, emotional breakthroughs, and lasting positive effects on well-being[1][2][3]. Harmine alone has minimal psychoactive effects at tolerated doses but enables the oral activity of DMT through MAO-A inhibition[4][6][7]. The combination can be delivered via various routes (e.g., nasal spray for DMT with buccal/oral tablet for harmine) and produces effects similar to those reported in ayahuasca ceremonies[5].

Other names
DMT/harmineDMT + harmine combinationayahuasca-inspired DMT/HAR formulation
02

Targets

HTR2A (Serotonin receptor 5-HT2A)DYRK1A (Dual-specificity tyrosine-phosphorylation-regulated kinase 1A)MAOA (Monoamine oxidase A)

Beyond the preview

Go deeper on dmt + harmine.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on dmt + harmine.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call